Ultime notizie per Orthofix Medical (NASDAQ:OFIX) Azioni

Orthofix Medical

Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries globally. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

Orthofix Medical Inc

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Forthofix.com%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=Orthofix+Medical+Inc&amp;index=1&amp;md5=f980520f95bd1a9234c20487cdf8b284">Orthofix Medical Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>), a leading global medical technology company, today announced the presentation of new data supporting the use of Orthofix's proprietary Pulsed Electromagnetic Field (PEMF) stimulation to increase fusion rates as an adjunct to lumbar spine fusion surgery. Patients treated with the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbonegrowththerapy.com%2Ftherapies%2Fspinal-fusion%2Fspinalstim-lumbar-fusion%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=SpinalStim&amp;index=2&amp;md5=c26f0cc0fb348022b3ce0b675596e790">SpinalStim</a>&#x2122; bone growth therapy device demonstrated a high rate of successful fusion with significant improvements in pain, function and quality of life, despite having risk factors for pseudarthrosis.
The abstract will be presented by Dr. Marc Weinstein, an orthopedic spine surgeon at the Florida Orthopaedic Institute in Tampa, Florida, at the North American Spine Society (NASS) Annual Meeting in Chicago, IL, on September 25, during the Research and Innovation Showcase in the McCormick Place West Lobby of the McCormick Convention Center.
During the NASS annual meeting, Orthofix is also highlighting a variety of new products including the full market launch of OsteoStrand&#x2122; Plus C. A 100% bone-derived graft, OsteoStrand Plus C is comprised of Demineralized Bone Matrix (DBM) fibers and Accell&#x2122; Bone Matrix, a dispersed form of DBM that provides immediate release of growth factors upon implantation and increases the concentration of growth factors in the product, and cancellous chips. Used as a bone graft material in fusion applications, the OsteoStrand Plus C features improved graft packability relative to non-chip containing options – for a denser fill and to ensure minimal graft displacement. Additionally, Orthofix is announcing the launch of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fm6disc.com%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=M6-C&amp;index=3&amp;md5=0f2300dfde3b2d3c8390c084ccf90edc">M6-C</a>&#x2122; Single-Use, Disposable Instrumentation sets, the first FDA-cleared, single-use, disposable instruments designed specifically for cervical disc arthroplasty.

News

OFIX

Orthofix Unveils New Spinal Fusion Products and Data, Highlighting Innovation at NASS Annual Meeting

Guidance

Orthofix Sees 2024 Net Sales $795M-$800M vs $793.79M Est.

Earnings

Earnings Beats

Earnings Misses

Orthofix Medical Q2 EPS $(0.88), Sales $198.60M Beat $195.23M Estimate

The Rodeo Telescopic Nail is a&nbsp;device indicated to surgically treat deformities or fractures in patients suffering from osteogenesis imperfecta (OI). The nail implant serves to stabilize the patient&#39;s limb while also elongating (or telescoping) to accommodate the natural growth of pediatric patients.

Health Care

General

Orthofix Medical Has Received FDA 510(K) Clearance To Market Its Rodeo Telescopic Nail

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Piper Sandler cut the price target for ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) from $24 to $15. Piper Sandler analyst Brent Bracelin downgraded the stock from Overweight to Neutral. ZoomInfo Technologies shares fell 3.6% to close at $16.02 on Tuesday. <a href="https://www.benzinga.com/quote/ZI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted the price target for Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) from $130 to $140. Baird analyst William Power upgraded the stock from Neutral to Outperform. Datadog shares fell 11.5% to close at $112.40 on Tuesday. <a href="https://www.benzinga.com/quote/DDOG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased MoneyLion Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) price target from $90 to $100. Needham analyst Kyle Peterson maintained a Buy rating. MoneyLion shares rose 0.2% to close at $71.53 on Tuesday. <a href="https://www.benzinga.com/quote/ML/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth MKM raised the price target for Orthofix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) from $15 to $20. Roth MKM analyst Jason Wittes upgraded the stock from Neutral to Buy. Orthofix Medical shares rose 3.2% to close at $13.89 on Tuesday. <a href="https://www.benzinga.com/quote/OFIX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) price target from $603 to $671. Baird analyst Eric Coldwell maintained an Outperform rating. McKesson shares rose 2.3% to close at $545.75 on Tuesday. <a href="https://www.benzinga.com/quote/MCK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho increased Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) price target from $70 to $71. Mizuho analyst Nitin Kumar maintained a Neutral rating. Occidental Petroleum shares gained 0.1% to close at $65.07 on Tuesday. <a href="https://www.benzinga.com/quote/OXY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity raised the price target for Confluent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) from $28 to $35. Canaccord Genuity analyst Kingsley Crane upgraded the stock from Hold to Buy. Confluent shares fell 2.8% to close at $27.83 on Tuesday. <a href="https://www.benzinga.com/quote/CFLT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Rosenblatt cut Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) price target from $76 to $64. Rosenblatt analyst Andrew Bond downgraded the stock from Buy to Neutral. Nasdaq shares fell 1.1% to close at $60.90 on Tuesday. <a href="https://www.benzinga.com/quote/NDAQ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B. Riley Securities slashed Crexendo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) price target from $6.75 to $5.75. B. Riley Securities analyst Josh Nichols upgraded the stock from Neutral to Buy. Crexendo shares fell 2.1% to close at $4.65 on Tuesday. <a href="https://www.benzinga.com/quote/CXDO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut Jack in the Box Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) price target from $81 to $67. Piper Sandler analyst Brian Mullan maintained a Neutral rating. Jack in the Box shares rose 0.02% to close at $54.92 on Friday. <a href="https://www.benzinga.com/quote/JACK/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/05/38692433/investor-sentiment-falls-further-dow-gains-for-fifth-session">Investor Sentiment Falls Further, Dow Gains For Fifth Session</a>

Price Target

Markets

Trading Ideas

CFLT

CXDO

DDOG

JACK

NDAQ

Datadog To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Wednesday

Roth MKM analyst Jason Wittes upgrades Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) from Neutral to Buy and raises the price target from $15 to $20.

Upgrades

Analyst Ratings

Roth MKM Upgrades Orthofix Medical to Buy, Raises Price Target to $20

Orthofix Cuts FY24 Revenue Outlook From $785M - $795M To $790M - $795M Vs. $790.82M Est.

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.33) by 187.88 percent. This is a 850 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $188.60 million which beat the analyst consensus estimate of $184.13 million by 2.43 percent. This is a 7.65 percent increase over sales of $175.20 million the same period last year.

Orthofix Medical Q1 EPS $(0.95) Misses $(0.33) Estimate, Sales $188.60M Beat $184.13M Estimate

JMP Securities analyst David Turkaly reiterates Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Market Perform.

Reiteration

JMP Securities Reiterates Market Perform on Orthofix Medical

Roth MKM analyst Jason Wittes maintains Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Neutral and raises the price target from $12 to $15.

Roth MKM Maintains Neutral on Orthofix Medical, Raises Price Target to $15

WIIM

Orthofix Medical shares are trading higher after the company reported better-than-expected Q4 revenue results and issued FY24 net sales guidance above estimates.

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.08) by 637.5 percent. This is a 68.57 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $200.41 million which beat the analyst consensus estimate of $195.31 million by 2.61 percent. This is a 63.97 percent increase over sales of $122.23 million the same period last year.

Orthofix Medical Earlier Reported Q4 EPS $(0.59) Misses $(0.08) Estimate, Sales $200.41M Beat $195.31M Estimate

Non-GAAP adjusted EBITDA of&nbsp;$62 million&nbsp;to&nbsp;$67 million, representing a&nbsp;$15.7 million&nbsp;to&nbsp;$20.7 million&nbsp;increase, over the full year 2023
<div>Non-GAAP adjusted EBITDA of&nbsp;$62 million&nbsp;to&nbsp;$67 million, representing a&nbsp;$15.7 million&nbsp;to&nbsp;$20.7 million&nbsp;increase, over the full year 2023</div>

Orthofix Expects 2024 Net Sales To Range $785M-$795M (Est. $741.55M), Expects To Exit Q4 2024 Free Cash Flow Positive

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) reported $200.40 million in sales this quarter. This is a 63.95 percent increase over sales of $122.23 million the same period last year.

Orthofix Medical Q4 Sales $200.40M Up From $122.23M YoY

<h3>Companies Reporting Before The Bell</h3>
&bull; NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.
&bull; Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is estimated to report quarterly earnings at $2.22 per share on revenue of $29.33 billion.
&bull; 2seventy bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) is expected to report quarterly loss at $0.99 per share on revenue of $14.71 million.
&bull; CLPS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPS#NASDAQ">CLPS</a>) is expected to report earnings for its first quarter.
&bull; Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) is projected to report quarterly loss at $0.50 per share on revenue of $350 thousand.
&bull; Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $183.67 million.
&bull; Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) is projected to report quarterly loss at $1.39 per share on revenue of $2.55 million.
&bull; Consolidated Comms Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSL#NASDAQ">CNSL</a>) is likely to report quarterly loss at $0.36 per share on revenue of $276.94 million.
&bull; CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) is likely to report quarterly earnings at $0.24 per share on revenue of $146.61 million.
&bull; 908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) is expected to report quarterly loss at $0.26 per share on revenue of $14.16 million.
&bull; Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) is projected to report quarterly loss at $0.26 per share on revenue of $19.85 million.
&bull; Broadwind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWEN#NASDAQ">BWEN</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $50.15 million.
&bull; Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) is projected to report quarterly loss at $0.03 per share on revenue of $541.17 million.
&bull; Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $84.02 million.
&bull; Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $9.00 million.
&bull; L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $129.35 million.
&bull; Rand Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAND#NASDAQ">RAND</a>) is expected to report earnings for its fourth quarter.
&bull; Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) is likely to report earnings for its fourth quarter.
&bull; Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) is projected to report quarterly loss at $0.26 per share on revenue of $17.33 million.
&bull; First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $237.53 million.
&bull; Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $20.00 million.
&bull; SmartRent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) is likely to report quarterly loss at $0.01 per share on revenue of $59.49 million.
&bull; Ferguson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) is estimated to report quarterly earnings at $1.85 per share on revenue of $6.77 billion.
&bull; Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $41.78 million.
&bull; Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) is likely to report quarterly loss at $0.10 per share on revenue of $41.65 million.
&bull; V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $1.01 billion.
&bull; Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) is likely to report earnings for its fourth quarter.
&bull; Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $196.19 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is estimated to report quarterly earnings at $0.80 per share on revenue of $197.70 million.
&bull; Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is estimated to report quarterly earnings at $0.88 per share on revenue of $4.39 billion.
&bull; BlackRock Cap Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKCC#NASDAQ">BKCC</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $20.32 million.
&bull; Presto Automation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) is likely to report earnings for its fourth quarter.
&bull; Kingsway Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFS#NYSE">KFS</a>) is likely to report earnings for its fourth quarter.
&bull; Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) is expected to report quarterly loss at $0.19 per share on revenue of $293.53 million.
&bull; Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) is likely to report earnings for its fourth quarter.
&bull; TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) is likely to report quarterly loss at $0.08 per share on revenue of $1.00 million.
&bull; Entravision Comms (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVC#NYSE">EVC</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $308.47 million.
&bull; Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) is projected to report quarterly loss at $0.87 per share on revenue of $10.58 million.
&bull; Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) is likely to report quarterly loss at $3.66 per share on revenue of $73.50 million.
&bull; Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) is expected to report quarterly loss at $0.62 per share on revenue of $8.01 million.
&bull; Allient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNT#NASDAQ">ALNT</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $132.56 million.
&bull; Bristow Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTOL#NYSE">VTOL</a>) is projected to report quarterly earnings at $0.54 per share on revenue of $329.20 million.
&bull; Greenlight Capital Re (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLRE#NASDAQ">GLRE</a>) is estimated to report earnings for its fourth quarter.
&bull; Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $34.10 million.
&bull; Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) is projected to report quarterly loss at $1.07 per share on revenue of $1.06 million.
&bull; Socket Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCKT#NASDAQ">SCKT</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $4.91 million.
&bull; Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) is expected to report quarterly loss at $0.40 per share on revenue of $1.95 million.
&bull; Park-Ohio Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PKOH#NASDAQ">PKOH</a>) is likely to report quarterly earnings at $0.55 per share on revenue of $386.45 million.
&bull; W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $138.42 million.
&bull; Cadre Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDRE#NYSE">CDRE</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $121.79 million.
&bull; Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $14.50 million.
&bull; Agiliti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGTI#NYSE">AGTI</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $291.41 million.
&bull; Nuvei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEI#NASDAQ">NVEI</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $319.51 million.
&bull; Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) is estimated to report quarterly earnings at $0.84 per share on revenue of $283.00 million.
&bull; Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $152.30 million.
&bull; Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) is likely to report quarterly loss at $0.08 per share on revenue of $11.63 million.
&bull; Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) is expected to report earnings for its fourth quarter.
&bull; MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $74.86 million.
&bull; Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) is likely to report earnings for its fourth quarter.
&bull; Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) is expected to report quarterly loss at $0.02 per share on revenue of $49.27 million.
&bull; American Public Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $150.47 million.
&bull; Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $249.68 million.
&bull; Crexendo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $13.80 million.
&bull; Aeva Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NYSE">AEVA</a>) is likely to report quarterly loss at $0.15 per share on revenue of $1.57 million.
&bull; LSB Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXU#NYSE">LXU</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $127.21 million.
&bull; PlayAGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGS#NYSE">AGS</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $92.57 million.
&bull; Full House Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLL#NASDAQ">FLL</a>) is likely to report quarterly loss at $0.14 per share on revenue of $63.13 million.
&bull; CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is expected to report quarterly earnings at $0.82 per share on revenue of $839.04 million.
&bull; HashiCorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCP#NASDAQ">HCP</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $149.29 million.
&bull; Banco BBVA Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAR#NYSE">BBAR</a>) is estimated to report earnings for its fourth quarter.
&bull; NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) is expected to report quarterly loss at $0.31 per share on revenue of $17.46 million.
&bull; Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) is projected to report earnings for its fourth quarter.
&bull; Ooma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $61.46 million.
&bull; ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) is likely to report quarterly loss at $0.13 per share on revenue of $119.59 million.
&bull; ODDITY Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) is expected to report earnings for its fourth quarter.
&bull; NewtekOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWT#NASDAQ">NEWT</a>) is projected to report quarterly earnings at $0.58 per share on revenue of $63.35 million.
&bull; Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) is expected to report quarterly earnings at $0.38 per share on revenue of $262.95 million.
&bull; Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) is projected to report earnings for its fourth quarter.
&bull; Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) is likely to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AEVA

AGTI

ALNT

AOMR

APEI

AQST

AXGN

BASE

BBAR

BKCC

BNGO

BWEN

CDRE

CECO

CERS

CGEN

CHPT

CIFR

CLPS

CNSL

CPIX

CRCT

CRWD

DAVE

FERG

FSTR

FWRG

GBTG

GLRE

ISPO

MASS

MCRB

MLNK

MRNS

NEWT

NPCE

NUWE

NVEI

NYXH

OOMA

PKOH

PRST

PSTV

RAND

RIGL

ROST

RSKD

SCKT

SEAT

SMLR

SMRT

SOPH

STIM

TCON

TSVT

VTOL

WEYS

Earnings Scheduled For March 5, 2024

Contracts

Orthofix Medical Has Entered Into An Agreement With MRIGuidance To Distribute Its BoneMRI Imaging Software In The U.S. The Company Also Announced The Completion Of The World's First Eight Cases Utilizing BoneMRI Software With 7D's FLASH Navigation System

Management

Orthofix Medical Announced That Julie Andrews Has Officially Stepped Into The Role Of Chief Financial Officer

Orthofix Medical shares are trading higher after the company reported preliminary Q4 and FY23 net sales guidance above estimates.

U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday.
Shares of Acuity Brands, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ayi#NYSE">AYI</a>) rose sharply Tuesday&rsquo;s session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/01/36552253/acuity-brands-shines-in-q1-stock-hits-52-week-high">first-quarter earnings</a>.
Acuity Brands reported a first-quarter FY24 net sales decline of 9% year-over-year to $934.7 million, marginally missing the consensus of $935.1 million. Adjusted EPS of $3.72 beat the consensus of $3.23.
Acuity Brands shares jumped 10.2% to $225.51 on Tuesday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Juniper Networks, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnpr#NYSE">JNPR</a>) shares gained 21.5% to $36.71. Hewlett Packard Enterprise Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hpe#NYSE">HPE</a>) is reportedly in advanced discussions to acquire networking equipment competitor Juniper Networks.</li>
<li>Accolade, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/accd#NASDAQ">ACCD</a>) jumped 17.2% to $13.61 following third-quarter results.</li>
<li>Century Aluminum Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cenx#NASDAQ">CENX</a>) shares rose 14.4% to $12.18. B. Riley Securities upgraded Century Aluminum from Neutral to Buy and raised the price target from $10 to $14.</li>
<li>ACM Research, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acmr#NASDAQ">ACMR</a>) surged 12.8% to $19.22. ACM Research said it sees FY23 revenue of $530 million to $545 million.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxrx#NASDAQ">RXRX</a>) gained 10.9% to $13.98.</li>
<li>Nukkleus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nukk#NASDAQ">NUKK</a>) gained 9.6% to $2.27.</li>
<li>Wheels Up Experience Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/up#NYSE">UP</a>) jumped 9.6% to $4.66.</li>
<li>Urban Outfitters, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/urbn#NASDAQ">URBN</a>) climbed 9.1% to $39.17 after the company reported a 10% increase in total company net sales for the two months ended Dec. 31, 2023.</li>
<li>Sotera Health Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shc#NASDAQ">SHC</a>) rose 9.1% to $17.22. Sotera Health presented FY23 revenue guidance of $1.04 billion to $1.05 billion at 42nd Annual J.P. Morgan Healthcare Conference.</li>
<li>NextNav Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nn#NASDAQ">NN</a>) gained 9% to $5.04.</li>
<li>MaxCyte, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mxct#NASDAQ">MXCT</a>) rose 8.9% to $5.00 after the company announced strong preliminary fourth-quarter and full year 2023 revenue results.</li>
<li>IGM Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/igms#NASDAQ">IGMS</a>) gained 8.5% to $12.04.</li>
<li>Orthofix Medical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ofix#NASDAQ">OFIX</a>) gained 8.4% to $14.40. Orthofix Medical reported preliminary FY23 net sales of $746.3 million versus consensus of $741.52 million.</li>
<li>Establishment Labs Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/esta#NASDAQ">ESTA</a>) rose 8.4% to $29.95. Establishment Labs announced a $50 Million private placement and preliminary unaudited financial results for the fourth quarter and fiscal year 2023.</li>
<li>Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>) gained 8.2% to $144.72 after the company reported preliminary FY23 consolidated revenue guidance above estimates.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srpt#NASDAQ">SRPT</a>) gained 6.6% to $109.40. Wedbush analyst Andreas Argyrides reiterated Sarepta Therapeutics with an Outperform and maintained a $224 price target.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36557687/dow-tumbles-over-200-points-us-trade-gap-narrows-in-november"> Dow Tumbles Over 200 Points; US Trade Gap Narrows In November </a>

Penny Stocks

Small Cap

Intraday Update

Movers

ACCD

ACMR

CENX

ESTA

IGMS

ILMN

JNPR

MXCT

NUKK

RXRX

SRPT

URBN

Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday

Orthofix Medical Reports Preliminary FY23 Net Sales Of $746.3M Versus Consensus Of $741.52M, Up 62% Y/Y On Reported Basis And 61.5% On Constant Currency Basis

Orthofix gets FDA clearance for Rodeo Telescopic Nail

In a report released today, David Turkaly from JMP Securities reiterated a Hold rating on Orthofix (OFIX – Research Report). The company's shares c...

JMP Securities Reaffirms Their Hold Rating on Orthofix (OFIX)

Orthofix (OFIX) just unveiled an announcement. At the Annual Meeting, the Company successfully established a quorum with over 32 million shares rep...

Orthofix Shareholders Approve Board and Key Proposals

Orthofix Q2 2024 Earnings Preview

Orthofix (OFIX) has provided an announcement. The Company plans to utilize its corporate investor relations presentation in various communications ...

Orthofix Outlines Investor Relations Strategy for Fiscal Year

Orthofix reports mixed Q2 results; raises FY24 outlook

Orthofix Medical Inc. (OFIX) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Orthofix Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/ofix-stock-quote/">OFIX</a>) just reported results for the second quarter of 2024.<ul><li>Orthofix Medical reported earnings per share of 5 cents. This was above the analyst estimate for EPS of -19 cents.</li><li>The company reported revenue of $198.62 million.</li><li>This was 1.74% better than the analyst estimate for revenue of $195.23 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ofix-stock-earnings-orthofix-medical-for-q2-of-2024/">OFIX Stock Earnings: Orthofix Medical Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OFIX Stock Earnings: Orthofix Medical Beats EPS, Beats Revenue for Q2 2024

JMP Securities Keeps Their Hold Rating on Orthofix (OFIX)

THE LAWSUIT: A class action securities lawsuit was filed against Orthofix Medical Inc. (OFIX) that seeks to recover losses of Orthofix shareholders...

Levi & Korsinsky LLP Notifies Orthofix Medical Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – OFIX

Legal

Press Releases

OFIX Investors: If You Sustained Significant Losses in Orthofix Medical Inc. Contact Shareholder Rights Law Firm Robbins LLP for Information About the Pending Class Action Lawsuit

OFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orthofix, Spire Global, DexCom, and Methode Electronics and Encourages Investors to Contact the Firm

ORTHOFIX MEDICAL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Orthofix Medical, Inc. - OFIX

The Gross Law Firm Notifies Shareholders of Orthofix Medical Inc.(OFIX) of a Class Action Lawsuit and an Upcoming Deadline

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orthofix Medical Inc. (OFIX)

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Orthofix Medical Inc. - OFIX

OFIX Investors Have Opportunity to Lead Orthofix Medical Inc. Securities Fraud Lawsuit

SHAREHOLDER ALERT: Holzer & Holzer, LLC Reminds Investors of the October 21, 2024 Lead Plaintiff Deadline in Class Action Lawsuits Filed on Behalf of DexCom, Inc. (DXCM), Orthofix Medical Inc. (OFIX), and Spire Global, Inc. (SPIR) Shareholders

Comments

Orthofix Medical

Notizie

Ultime notizie per Orthofix Medical (NASDAQ:OFIX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO